AR027656A1 - Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa - Google Patents

Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa

Info

Publication number
AR027656A1
AR027656A1 ARP010101185A ARP010101185A AR027656A1 AR 027656 A1 AR027656 A1 AR 027656A1 AR P010101185 A ARP010101185 A AR P010101185A AR P010101185 A ARP010101185 A AR P010101185A AR 027656 A1 AR027656 A1 AR 027656A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
glucogeno
fosforilasa
inhibitors
polymer
Prior art date
Application number
ARP010101185A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR027656A1 publication Critical patent/AR027656A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

Composiciones farmacéuticas que contienen un inhibidor de la glucogeno-fosforilasa y como mínimo un polímero que aumenta la concentracion. La composicionpuede ser una mezcla física simple de un inhibidor de la glucogeno-fosforilasa y un polímero que aumenta la concentracion, o una dispersion de un inhibidor dela glucogeno-fosforilasa y un polímero.
ARP010101185A 2000-03-16 2001-03-14 Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa AR027656A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18994200P 2000-03-16 2000-03-16

Publications (1)

Publication Number Publication Date
AR027656A1 true AR027656A1 (es) 2003-04-09

Family

ID=22699402

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101185A AR027656A1 (es) 2000-03-16 2001-03-14 Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa

Country Status (32)

Country Link
US (1) US20010053778A1 (es)
EP (1) EP1263414A1 (es)
JP (1) JP2003526654A (es)
KR (1) KR20020081445A (es)
CN (1) CN1418089A (es)
AP (1) AP2002002621A0 (es)
AR (1) AR027656A1 (es)
AU (1) AU2001242669A1 (es)
BG (1) BG107037A (es)
BR (1) BR0109189A (es)
CA (1) CA2403241A1 (es)
CO (1) CO5280087A1 (es)
CZ (1) CZ20022955A3 (es)
EA (1) EA200200858A1 (es)
EE (1) EE200200530A (es)
HU (1) HUP0204583A2 (es)
IL (1) IL151320A0 (es)
IS (1) IS6508A (es)
MA (1) MA26882A1 (es)
MX (1) MXPA02009097A (es)
NO (1) NO20024386L (es)
OA (1) OA12232A (es)
PA (1) PA8513601A1 (es)
PE (1) PE20011184A1 (es)
PL (1) PL360780A1 (es)
SK (1) SK12622002A3 (es)
SV (1) SV2002000343A (es)
TN (1) TNSN01040A1 (es)
TR (1) TR200202184T2 (es)
WO (1) WO2001068055A1 (es)
YU (1) YU67202A (es)
ZA (1) ZA200207290B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3227A1 (fr) * 1999-12-23 2001-07-05 Pfizer Prod Inc Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
DE60238193D1 (de) * 2001-06-22 2010-12-16 Pfizer Prod Inc Pharmazeutische zusammensetzungen, enthaltend adsorbate eines arzneimittels in amorpher form
JP2004534812A (ja) 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 薬物および中性ポリマーの分散物の医薬組成物
BR0211028A (pt) * 2001-06-22 2004-06-15 Pfizer Prod Inc Solução aquosa, método para formação de associações de fármaco e polìmero, composições farmacêuticas, método para formação de uma composição farmacêutica e produto
JP4865989B2 (ja) 2002-02-01 2012-02-01 ベンド・リサーチ・インコーポレーテッド 改良された噴霧乾燥装置を使用する均質な噴霧乾燥された固体の非晶質薬物分散物を製造する方法
JP2005523262A (ja) 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
KR100758045B1 (ko) 2002-02-01 2007-09-11 화이자 프로덕츠 인크. 압력 노즐을 이용하여 균질한 분무 건조된 비결정질 고체약물 분산제를 제조하는 방법
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
BRPI0413277A (pt) * 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
BRPI0418330A (pt) * 2003-12-31 2007-05-02 Pfizer Prod Inc composições sólidas de drogas de solubilidade baixa e poloxámeros
WO2005085245A1 (en) 2004-03-08 2005-09-15 Prosidion Limited Pyrrolopyridine-2-carboxylic acid hydrazides
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
WO2014031419A1 (en) 2012-08-24 2014-02-27 Dow Global Technologies Llc Novel esterified cellulose ethers of high molecular weight and homogeneity
HUE057701T2 (hu) 2012-09-11 2022-05-28 Medivation Prostate Therapeutics Llc Enzalutamid kiszerelési formái
CA3128535A1 (en) * 2013-07-19 2015-01-22 Siga Technologies, Inc. Amorphous tecovirimat preparation
CN103709171B (zh) * 2014-01-20 2015-09-16 武汉大学 具有哒嗪并[3,4-b]吲哚骨架结构的衍生物及其合成方法
CN112442022B (zh) * 2019-09-02 2022-05-20 承德医学院 苯并嗪-4-酮类化合物、其制备方法及医药用途
US11291701B1 (en) * 2021-02-04 2022-04-05 Seed Edibles Orally disintegrating, sublingual and buccal formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0832066T3 (da) * 1995-06-06 2001-11-19 Pfizer Substituerede N-(indol-2-carbonyl)amider og derivater som glycogenphosphorylaseinhibitorer
ATE206702T1 (de) * 1995-06-06 2001-10-15 Pfizer Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren
DK0901786T3 (da) * 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
TR200202184T2 (tr) 2003-01-21
BG107037A (bg) 2003-04-30
EE200200530A (et) 2004-04-15
ZA200207290B (en) 2003-09-11
IL151320A0 (en) 2003-04-10
US20010053778A1 (en) 2001-12-20
CA2403241A1 (en) 2001-09-20
BR0109189A (pt) 2003-05-27
TNSN01040A1 (fr) 2005-11-10
AU2001242669A1 (en) 2001-09-24
IS6508A (is) 2002-08-16
CO5280087A1 (es) 2003-05-30
PA8513601A1 (es) 2004-08-31
MA26882A1 (fr) 2004-12-20
HUP0204583A2 (hu) 2003-04-28
PE20011184A1 (es) 2001-11-15
MXPA02009097A (es) 2003-03-12
OA12232A (en) 2006-05-10
NO20024386L (no) 2002-11-13
EP1263414A1 (en) 2002-12-11
WO2001068055A1 (en) 2001-09-20
YU67202A (sh) 2006-01-16
AP2002002621A0 (en) 2002-09-30
CN1418089A (zh) 2003-05-14
CZ20022955A3 (cs) 2003-09-17
KR20020081445A (ko) 2002-10-26
PL360780A1 (en) 2004-09-20
NO20024386D0 (no) 2002-09-13
JP2003526654A (ja) 2003-09-09
SK12622002A3 (sk) 2004-02-03
EA200200858A1 (ru) 2003-02-27
SV2002000343A (es) 2002-07-03

Similar Documents

Publication Publication Date Title
AR027656A1 (es) Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
PA8564901A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
PA8523901A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester
DK1515702T6 (da) Misbrugssikret indgivelsesform
SE0102315D0 (sv) Compounds
AR038207A1 (es) Composicion farmaceutica dispersable oralmente de agomelatina
CY1116023T1 (el) Μορφες φαρμακευτικης δοσολογιας παρατεταμενης απελευθερωσης με περιγραμματα διαλυτοποιησης ελαχιστοποιημενης εξαρτησης απο το ph
PT1117440E (pt) Composicoes farmaceuticas que contem paclitaxel
ECSP056229A (es) Una composición farmacéutica que comprende formas polimórficas de 3-(4-amino-1-oxo-1.3 dyhidro-isoindol-2-il)-piperidina-2,6-diona para el tratamiento y manejo de cánceres
ECSP109852A (es) Uso de homo y copolímeros para la estabilización de formulaciones de principios activos
ECSP024382A (es) Inhibidores de proteasa de serina
TR200100054T2 (tr) Paroksetin metansülfonat
AR023641A1 (es) Una composicion de copolimeros de propileno cristalinos, un procedimiento para prepararla, y una pelicula o lamina monocapa o multicapa que comprende adicha composicion
GB0226434D0 (en) Combination product
TR200200606T2 (tr) Lipaz inhibitörleri içeren dispersiyon terkipleri.
DK0991424T3 (da) Farmaceutiske præparater omfattende en inhibitor for aldosereduktase og en inhibitor for ACE
BR0000544A (pt) Poliolefinas de metaloceno estabilizadas
RS51534B (en) NEW COMPOUND OF SINUSOID IF CURRENT INHIBITORS AND CALCIUM INHIBITOR AND PHARMACEUTICAL MIXTURE CONTAINED BY IT
ATE354291T1 (de) Zusammensetzungen enthaltend mindestens kürbisöl und borretschöl, deren verwendung als arzneimittel, dermatikum oder dermatokosmetische zusammensetzung
MXPA03001455A (es) Compuestos de pirazol, composiciones farmaceuticas y metodos para modular o inhibir la actividad del amiloide-beta-peptido asociado a reticulo endoplasmico y l-3-hidroxiacil-coa-deshidrogenasa.
DE602005010203D1 (de) Pharmazeutische zusammensetzung enthaltend 2,4-dichlorbenzylalkohol und amylmetakresol
DK1135169T3 (da) Anvendelse af et farmaceutisk præparat indeholdende et anticancermiddel og mindst et peptid.
UY26618A1 (es) Composiciones farmacéuticas de inhibidores de la gcomposiciones farmacéuticas de inhibidores de la glucógeno-fosforilasa
ATE392644T1 (de) Alpha-(1' -hydroxyalkyl)acrylate enthaltende beschichtungsmassen
AR031404A1 (es) Una composicion y metodo de aplicacion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal